TAIPEI, Taiwan, March 19, 2025 — Primo Biotechnology Co., Ltd. (Primo) is partnering with ABX advanced biochemical compounds GmbH (ABX) of Germany to introduce PB01 to Taiwan, addressing the increasing prevalence of prostate cancer there.
According to Taiwan Cancer Registry data, prostate cancer incidence and mortality have been steadily increasing [1], highlighting the pressing need for better diagnostic methods. Radelumin, a novel diagnostic radiotracer for prostate cancer, is already approved in France and several European nations [2]. Radelumin, and its Taiwanese counterpart PB01, utilizes advanced PET/CT imaging to precisely identify Prostate Specific Membrane Antigen (PSMA) expression, allowing doctors to accurately detect and monitor prostate cancer.
Since its launch in Europe in 2021 [2], Radelumin has become a popular tool for early detection, staging, and monitoring recurrence in high-risk prostate cancer patients. The ABX-Primo partnership seeks to introduce this essential diagnostic tool to Taiwan, improving the precision of cancer treatment.
Primo CEO’s statement: “Accurate diagnosis is the first step towards precision treatment. The launch of PB01 in Taiwan offers hope to Taiwanese prostate cancer patients and marks a significant step forward in precision radiological diagnostics for cancer care in the region.”
ABX CEO’s statement: “Primo is a strong partner in Taiwan, recognized for its reliable manufacturing capabilities. We believe in PB01’s potential in the Taiwanese market and anticipate that this technology will become a key component of precision medicine for prostate cancer.”
About ABX advanced biochemical compounds GmbH
ABX, based in Germany, is a global leader in producing materials for radiopharmaceuticals. It focuses on researching, developing, and manufacturing precursors, reagent kits, and cassettes for radiochemical labeling, offering high-quality products and services across many countries. ABX is dedicated to innovation and quality, thereby advancing nuclear medicine globally.
About Primo Biotechnology Co., Ltd.
Primo is a leading biotech company specializing in the development and manufacture of radiopharmaceuticals. With certified international facilities, Primo is dedicated to bringing hope and a future to cancer patients through precision molecular imaging technology. Based in Taipei, the company works with local and international partners to advance precision cancer care. For more information, visit and follow on Facebook and LinkedIn.
Source:
[1] Taiwan ministry of health and welfare national health service, Taiwan cancer registry.
[2] ABX’s press release in 2023.
Media Contact: Sunny Chen
Job Title: Marketing Manger
Email:
Company: Primo Biotechnology Co., Ltd.
Website:
